GLK-221

GLK-221 is an investigational topical ophthalmic solution developed by Glaukos Corporation for the treatment of keratoconus. It is designed as a non-invasive, pharmacological alternative to traditional corneal collagen cross-linking (CXL) procedures, which typically require the removal of the corneal epithelium and exposure to ultraviolet (UV) light. GLK-221 is administered twice daily and works by promoting the natural cross-linking of collagen fibers within the corneal stroma to increase structural rigidity and halt the progressive thinning and protrusion characteristic of the disease. As of late 2023, the drug is being evaluated in a Phase 2 multicenter, randomized, double-masked, placebo-controlled clinical trial to assess its safety and efficacy in subjects with keratoconus.

Other names

GLK-221 Ophthalmic SolutionGLK221 Ophthalmic SolutionGLK 221 Ophthalmic Solution